Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 4/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.42 |
| ▸ | PRNP | P04156 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | PAM | P19021 | 1/20 | 0.41 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13988071 | 1.00 | ALDH1A1 (0.57) | ALDH1A1MAPTKDM4ETHRBALOX15 | |
| SCHEMBL26946036 | 0.86 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4ETHRBALOX15 | |
| SCHEMBL25340359 | 0.83 | MAPT (0.57) | ALDH1A1MAPTKDM4ETHRBALOX15 | |
| SCHEMBL12989759 | 0.82 | ACE (0.48) | ACE | |
| SCHEMBL18979837 | 0.82 | ALDH1A1 (0.50) | ALDH1A1MAPTKDM4ETHRBALOX15 | |
| SCHEMBL18979836 | 0.82 | ALDH1A1 (0.50) | ALDH1A1MAPTKDM4ETHRBALOX15 | |
| SCHEMBL31555346 | 0.82 | ALDH1A1 (0.50) | ALDH1A1MAPTKDM4ETHRBALOX15 | |
| SCHEMBL6308419 | 0.81 | MAPT (0.59) | ALDH1A1MAPTKDM4ETHRBALOX15 | |
| SCHEMBL24067699 | 0.81 | MAPT (0.59) | ALDH1A1MAPTKDM4ETHRBALOX15 | |
| SCHEMBL4952983 | 0.81 | MAPT (0.59) | ALDH1A1MAPTKDM4ETHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11479579-B2 | Therapeutic compounds and methods | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-10-25 | — | — | US | disclosed |
| US-20210277055-A1 | THERAPEUTIC COMPOUNDS AND METHODS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-09-09 | — | — | US | disclosed |
| US-10590159-B2 | Lincomycin biosynthetic intermediates, method for preparation, and use thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2020-03-17 | — | — | US | disclosed |
| US-9468625-B2 | Organonitro thioether compounds and medical uses thereof | EPICENTRX, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9468625-B2 | Organonitro thioether compounds and medical uses thereof | EPICENTRX, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9457014-B2 | Cysteine prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9457014-B2 | Cysteine prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160081987-A1 | Cysteine Prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160081981-A1 | ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF | RADIORX, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160081987-A1 | Cysteine Prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160081981-A1 | ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF | RADIORX, INC. | 2016-03-24 | — | — | US | disclosed |
| US-9139519-B2 | Organonitro thioether compounds and medical uses thereof | EPICENTRX, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150045312-A1 | Use of Compounds Elevating Glutathione Levels for the Treatment of Autism, Autistic Spectrum Disorders and Fragile X Syndrome | PROMENTIS PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20140349988-A1 | ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF | RADIORX, INC. (US) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479579-B2 | Therapeutic compounds and methods | SNCA, PARK7, PSEN2 | ALDH1A1 434/4885MAPT 18/4885KDM4E 4689/4885 |
| US-10590159-B2 | Lincomycin biosynthetic intermediates, method for preparation, and use thereof | COASY, DHPS, DCXR | ALDH1A1 1335/4885MAPT 3458/4885KDM4E 2547/4885 |
| US-20150045312-A1 | Use of Compounds Elevating Glutathione Levels for the Treatment of Autism, Autistic Spectrum Disorders and Fragile X Syndrome | SLC7A11, SLC1A2, GSS | ALDH1A1 1620/4885MAPT 1933/4885KDM4E 4468/4885 |
| US-20160081987-A1 | Cysteine Prodrugs | SLC7A11, GCLC, CTH | ALDH1A1 636/4885MAPT 10/4885KDM4E 3877/4885 |
| US-20140349988-A1 | ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF | SLC22A8, SLCO2A1, SLCO2B1 | ALDH1A1 1453/4885MAPT 2777/4885KDM4E 747/4885 |
| US-20160081981-A1 | ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF | SLC22A8, XPOT, NPM1 | ALDH1A1 2447/4885MAPT 2770/4885KDM4E 1061/4885 |
| US-20210277055-A1 | THERAPEUTIC COMPOUNDS AND METHODS | SNCA, PARK7, PSEN2 | ALDH1A1 434/4885MAPT 18/4885KDM4E 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.